The NIH UH2 mechanism supports exploratory, pilot, or planning phases of innovative research projects that require substantial NIH programmatic involvement. UH2 awards are commonly paired with a subsequent UH3 implementation phase, forming a phased innovation structure similar to the R61/R33 model but under a cooperative agreement mechanism with closer NIH collaboration.

The UH2 phase is used to:

• establish feasibility and preliminary data

• complete planning and protocol development

• demonstrate proof-of-concept

• refine interventions, technologies, or methods

• meet clearly defined milestones required for advancement to UH3

A defining feature of UH2 awards is that they are milestone-driven and cooperative. NIH program staff work closely with investigators in project oversight, milestone assessment, coordination with other sites or consortia, and progression decisions. Advancement to a UH3 phase is not automatic and depends on successful completion of prespecified UH2 milestones.

UH2 mechanisms are commonly used in programs involving:

• early translational and implementation research

• multi-site pilot clinical trials or readiness activities

• technology development or validation studies

• large collaborative initiatives requiring structured ramp-up phases

• public–private or multi-institutional partnerships

Typical UH2 characteristics include:

• project periods often up to two years for the exploratory phase

• predefined, quantifiable milestones and decision points

• substantial NIH programmatic engagement and oversight

• a linked UH3 phase focused on full-scale implementation or expansion

Competitive UH2 applications clearly articulate:

• specific, measurable milestones tied to transition readiness

• feasibility data or strong rationale for phased development

• a well-defined plan for the subsequent UH3 phase

• collaborative structure and governance appropriate for a cooperative agreement

• outcome measures and decision criteria for milestone success

Reviewers evaluate significance, innovation, feasibility, investigator capability, strength of milestones, project management, and the appropriateness of cooperative agreement structure. Because UH2/UH3 mechanisms involve shared stewardship with NIH, clarity in roles, decision processes, and milestone criteria is essential.

At ScienceDocs, our team includes former NIH program officers, cooperative-agreement PIs, and implementation scientists experienced with phased cooperative mechanisms such as UH2/UH3. We assist applicants in crafting strong milestone frameworks, aligning phased aims, developing governance and coordination plans, and positioning projects for successful UH3 transition.

Please fill out our quote sheet to connect with a ScienceDocs UH2 grant writer and our expert consulting team.